Filters

Bax (Ser184) Antibody

Bax (Ser184) Antibody size: 0.1ml 281

Price 281
Size 0.1ml
Long nameBax (Ser184) Primary Polyclonal Antibody
Also known asBax (Ser184) PAb
CategoryPrimary Antibodies
ConjugationUnconjugated
Target AntigenBax Ser184
SpecificityThis is a highly specific antibody against Bax Ser184
Modification(s)Phosphorylation
Modification site(s)Ser184
ClonalityPolyclonal antibody
Clone numberPolyclonal antibody
Concentration1ug per 1ul
Immunogen range179-192/192
Subcellular locationHelical
SourceKLH conjugated synthetic phosphopeptide derived from human Bax around the phosphorylation site of Ser184
Gene ID number581
Swiss ProtQ07812
Tested Applications IF(IHC-P), IHC-P, WB
Recommended dilutions IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000)
Cross reactivity Mouse, Rat, Human
Cross reactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Background of the target antigen Promotes activation of CASP3, Under stress conditions, and antagonizing the apoptosis repressor BCL2 or its adenovirus homolog E1B 19k protein, and thereby apoptosis, leading to the release of cytochrome c that then triggers apoptosis, undergoes a conformation change that causes translocation to the mitochondrion membrane, Accelerates programmed cell death by binding to
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA
Synonym names Apoptosis regulator BAX, BAX, Bcl-2-like protein 4, Bcl2-L-4, BCL2L4
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°
Gene targetBax (Ser184)
Short nameBax (Ser184) Antibody
Technique antibodies against human proteins, antibodies for, Antibody
Alternative nameBCL2-associated X protein (Ser184) (Antibody to)
Alternative techniqueantibodies

Subscribe to our Newsletter